Growth Metrics

Nexalin Technology (NXL) Operating Leases (2021 - 2023)

Nexalin Technology's quarterly Operating Leases came in at $43026.0 in Q1 2023, up 864.06% quarter-over-quarter from $4463.0 in Q4 2022.

Nexalin Technology has reported Operating Leases for 3 years, with the latest figure at $43026.0 in Q1 2023.

  • For the quarter ending Q1 2023, Operating Leases changed N/A year-over-year to $43026.0; the trailing twelve-month figure through Mar 2023 stood at $43026.0 (changed N/A YoY), and the FY2022 full-year result was $4463.0, down 87.93% from the prior year.
  • Operating Leases for Q1 2023 stood at $43026.0, up from $4463.0 in the prior quarter.
  • The five-year high for Operating Leases was $43026.0 in Q1 2023, with the low at $4463.0 in Q4 2022.
  • Average Operating Leases over 3 years is $25524.0, with a median of $27303.5 recorded in 2021.
  • Peak annual rise in Operating Leases reached 87.93% in 2022, while the deepest fall reached 87.93% in 2022.
  • Tracing NXL's Operating Leases over 3 years: stood at $36973.0 in 2021, then tumbled by 87.93% to $4463.0 in 2022, then surged by 864.06% to $43026.0 in 2023.
  • The last three Operating Leases figures came in at $43026.0 (Q1 2023), $4463.0 (Q4 2022), and $17634.0 (Q3 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Nexalin Technology 11.19 Mn 8.48 Mn 13,133.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2023 43,026.00
Dec 31, 2022 4,463.00
Sep 30, 2022 17,634.00
Dec 31, 2021 36,973.00